Transcriptional profiling of leukocytes in critically ill COVID19 patients: implications for interferon response and coagulation by Gill, Sean E et al.
Western University 
Scholarship@Western 
Paediatrics Publications Paediatrics Department 
12-11-2020 
Transcriptional profiling of leukocytes in critically ill COVID19 
patients: implications for interferon response and coagulation 
Sean E Gill 
Claudia C Dos Santos 
David B O'Gorman 
David E Carter 
Eric K Patterson 
See next page for additional authors 
Follow this and additional works at: https://ir.lib.uwo.ca/paedpub 
 Part of the Pediatrics Commons 
Authors 
Sean E Gill, Claudia C Dos Santos, David B O'Gorman, David E Carter, Eric K Patterson, Marat Slessarev, 
Claudio Martin, Mark Daley, Michael R. Miller, Gediminas Cepinskas, and Douglas Fraser 
Transcriptional profiling of leukocytes 
in critically ill COVID19 patients: implications 
for interferon response and coagulation
Sean E. Gill1,2,3,10*† , Claudia C. dos Santos4†, David B. O’Gorman1,5, David E. Carter6, Eric K. Patterson1, 
Marat Slessarev1,3, Claudio Martin1,3, Mark Daley1,7, Michael R. Miller1,8, Gediminas Cepinskas1,9 
and Douglas D. Fraser1,2,8,11* on behalf of Lawson COVID19 Study Team
Abstract 
Background: COVID19 is caused by the SARS-CoV-2 virus and has been associated 
with severe inflammation leading to organ dysfunction and mortality. Our aim was to 
profile the transcriptome in leukocytes from critically ill patients positive for COVID19 
compared to those negative for COVID19 to better understand the COVID19-associ-
ated host response. For these studies, all patients admitted to our tertiary care inten-
sive care unit (ICU) suspected of being infected with SARS-CoV-2, using standardized 
hospital screening methodologies, had blood samples collected at the time of admis-
sion to the ICU. Transcriptome profiling of leukocytes via ribonucleic acid sequencing 
(RNAseq) was then performed and differentially expressed genes as well as significantly 
enriched gene sets were identified.
Results: We enrolled seven COVID19 + (PCR positive, 2 SARS-CoV-2 genes) and seven 
age- and sex-matched COVID19- (PCR negative) control ICU patients. Cohorts were 
well-balanced with the exception that COVID19− patients had significantly higher 
total white blood cell counts and circulating neutrophils and COVID19 + patients 
were more likely to suffer bilateral pneumonia. The mortality rate for this cohort of 
COVID19 + ICU patients was 29%. As indicated by both single-gene based and gene 
set (GSEA) approaches, the major disease-specific transcriptional responses of leuko-
cytes in critically ill COVID19 + ICU patients were: (i) a robust overrepresentation of 
interferon-related gene expression; (ii) a marked decrease in the transcriptional level 
of genes contributing to general protein synthesis and bioenergy metabolism; and (iii) 
the dysregulated expression of genes associated with coagulation, platelet function, 
complement activation, and tumour necrosis factor/interleukin 6 signalling.
Conclusions: Our findings demonstrate that critically ill COVID19 + patients on day 1 
of admission to the ICU display a unique leukocyte transcriptional profile that distin-
guishes them from COVID19− patients, providing guidance for future targeted studies 
exploring novel prognostic and therapeutic aspects of COVID19.
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Introduction
Coronavirus disease (COVID) 19 is continuing to spread rapidly throughout the 
world, negatively impacting infected individuals, the health systems that support 
them and the global economy. The novel coronavirus that causes COVID19, SARS-
CoV-2, was zoonotically derived from the Wuhan region, in Hubei Province, China in 
late 2019 [1, 2]. Patients infected with SARS-CoV-2 exhibit a range of symptoms from 
mild hypoxemia with preserved lung compliance, and a mild inflammatory response, 
to severe hypoxemia associated with loss of lung function and a dysregulated inflam-
matory response with sustained tumour necrosis factor (TNF) and serine proteases 
that typically necessitates admission to an intensive care unit (ICU) [3–6]. The overall 
mortality rate of individuals with COVID19 has been reported to be approximately 
3.4%; however, once COVID19 patients are admitted to the ICU, their mortality rate 
approximates 31–40% with a median of 9 days to ICU death [5–8].
Early reports have suggested that dysregulated cytokine response drives the severity 
of organ injury and dysfunction in COVID19 patients who require life support [5, 9, 
10]. Transcriptional profiling of whole blood from these patients indicate an early and 
dynamic inflammatory response with enhanced expression of interleukin 1β (IL1β) 
associated genes and T cell activation [11]. However, these observations were made in 
comparison to healthy controls, and the increased circulating levels of pro-inflamma-
tory cytokines observed in patients with COVID19 are also observed in other forms 
of sepsis and acute respiratory distress syndrome (ARDS) [4, 10]. Our aim was to 
transcriptionally profile COVID19-positive (COVID19 +) ICU patients in compari-
son to COVID19-negative (COVID19-) ICU patients with severe acute respiratory 
diseases/conditions [5–7].
Methods
Study participants and clinical data
This study was approved by the Human Subject Research Ethics Board at Western 
University [5–7]. Patients who were admitted to our academic ICU and suspected of 
having COVID19 based on standard hospital screening procedures and who had acute 
non-cardiogenic hypoxic respiratory failure requiring mechanical ventilation > 48  h 
were consecutively enrolled in the study. Patients were then separated into cohorts, 
either COVID19 + or COVID19−, based on detection of two SARS-CoV-2 viral 
genes using polymerase chain reaction (PCR). Patient baseline characteristics were 
recorded on admission and included age, sex, severity of illness scores, comorbidities, 
hematologic labs, creatinine, arterial partial pressure-to-inspired oxygen (P/F) ratio, 
chest X-ray findings and sepsis diagnosis using Sepsis 3.0 criteria [12]. Clinical inter-
ventions received in the ICU included use of antibiotics, anti-viral agents, systemic 
corticosteroids, vasoactive medications, renal replacement therapy, high-flow oxygen 
therapy, and mechanical ventilation (invasive and non-invasive). Final participant 
groups were constructed by identifying 7 COVID19 + patients and then matching to 
7 COVID19− patients by age and sex only [5–7]. These patients have been included 
in previous studies performed by our group and this is a retrospective evaluation of 
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the biological data from these patients [5–7]. Further, given the exploratory nature of 
the study, no sample size calculation was performed.
Blood draws
Blood was collected from patients upon ICU admission using standard operating proce-
dures to ensure all samples were treated rapidly and equally [5–7]. Blood was obtained 
via indwelling catheters and placed immediately on ice. Once transferred to a negative 
pressure hood, the blood was centrifuged and the buffy coat was isolated and frozen at 
− 80 °C. All samples were stored frozen in the Translational Research Centre, London, 
Ontario (directed by Dr. D.D. Fraser; https ://trans latio nalre searc hcent re.com/) until use 
and freeze/thaw cycles were avoided [13, 14].
RNA isolation
Buffy coat cells were homogenized in Trizol LS and centrifuged at 12,000 rcf to remove 
cell debris. Following chloroform extraction, RNA was isolated using the RNeasy Micro 
Plus Kit (Qiagen) according to the manufacturer’s protocol.
Illumina NextSeq next generation sequencing
All samples were sequenced at the London Regional Genomics Centre (Robarts Research 
Institute, London, Ontario, Canada; http://www.lrgc.ca) using the Illumina NextSeq 500 
(Illumina Inc., San Diego, CA).
Total RNA samples were quantified using the NanoDrop (Thermo Fisher Scientific, 
Waltham, MA) and quality was assessed using the Agilent 2100 Bioanalyzer (Agilent 
Technologies Inc., Palo Alto, CA) and the RNA 6000 Nano kit (Caliper Life Sciences, 
Mountain View, CA). Only samples with an RNA integrity number ≥ 6.0 were used. 
The samples were then processed using the Vazyme VAHTS Total RNA-seq (H/M/R) 
Library Prep Kit for Illumina (Vazyme, Nanjing, China), which includes ribosomal RNA 
(rRNA) reduction.
Briefly, samples were rRNA depleted, fragmented, and utilized for cDNA synthesis and 
PCR amplification with indexed primers to permit equimolar pooling of samples into 
one library. The pooled library size distribution was assessed on an Agilent High Sensi-
tivity DNA Bioanalyzer chip, and quantitated using the Qubit 2.0 Fluorometer (Thermo 
Fisher Scientific, Waltham, MA).
The library was sequenced on the Illumina NextSeq 500 as single end runs, 1 × 76 bp, 
using High Output v2 kits (75 cycles). Fastq data files were analysed using Partek Flow 
(St. Louis, MO; Additional file 1: Figure S1). After importation, the data were aligned to 
the Homo sapiens genome hg19 using STAR 2.7.3a and annotated using RefSeq Tran-
scripts 93. Features with more than 18 reads were normalized using Trimmed Mean 
of M-values (TMM) (https ://doi.org/10.1186/gb-2010-11-3-r25) followed by adding 
0.0001. Any batch effect due to the run date was removed using Partek Flow’s Remove 
batch effect tool based on the results of the principal component analysis (PCA) plot 
and a dissimilarity plot analysis (Fig. 1a and Additional file 2: Figure S2). The gene-spe-
cific analysis (GSA) function of Partek Flow was then used to determine differential gene 
expression in COVID19 + vs. COVID19− patients using Akaike Information Criteria 
corrected (AICc)—a repeated measure analysis using mixed models methodology. The 
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filtered gene list (fold change of 1.5 and FDR p-value ≤  0.0545) was then submitted to 
Metascape (https ://metas cape.org/gp/index .html#/main/step1 ) using express analy-
sis of H. sapiens gene IDs [15]. A subset of enriched terms were selected and rendered 
as a network plot, where terms with a similarity > 0.3 were connected by edges. Terms 
with the lowest p-values from each of the 20 clusters were selected, with the constraint 
that there are no more than 15 terms per cluster and no more than 250 terms in total. 
The network was visualized using Metascape, where each node represented an enriched 
term and was coloured first by cluster ID and then by p-value. The filtered gene list was 
also analysed for enriched KEGG pathway terms.
Gene set enrichment analysis (GSEA)
Functional enrichment of the cumulative changes in gene expression across a priori 
defined gene sets was performed in GSEA to avoid the limitations of single-gene dif-
ferential gene expression methods [16]. All 14,810 genes that passed quality control were 
included in this analysis. The MSigDB collection was used to perform three main enrich-
ment analyses: (i) Hallmark gene set (50 gene sets containing overlaps between MSigDB 
Fig. 1 Leukocytes from COVID19 + ICU patients have a unique transcriptional profile compared to 
leukocytes from COVID19- ICU patients. a Principal component analysis (PCA) plot of total leucocyte (buffy 
coat) RNA samples derived from COVID19-positive (COVID +) and negative (COVID−) patients after removing 
the batch effect of date and interaction between date and status, using all principal components and 
features contributing equally. b Volcano plot of 1311 genes (highlighted) differentially expressed between 
leucocyte RNA samples derived from COVID19 positive (COVID +) versus negative (COVID−) samples 
based on a filtering criterion of ± 1.5-Fold change and an FDR step-up p-value cut-off ≤ 0.0545. c Heat map 
of 1311 genes that were differentially expressed between leucocyte RNA samples derived from COVID19 
positive (COVID +) versus negative (COVID−) samples using average linkage, Euclidean distance metric and 
standardize normalization mode (shift mean to 0 and scale standard deviation to 1 on all features)
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collections that display coordinate expression); (ii) Canonical Pathways (C2, 2232 gene 
sets); and (iii) regulatory target gene sets (C3, transcription factors, 1137 gene sets) [17]. 
The gene sets included in the analysis were limited to those that contained between 10 
and 500 genes. Permutation was conducted 1000 times according to default-weighted 
enrichment statistics and by using a signal-to-noise metric to rank genes according to 
their differential expression levels across the COVID19 + vs. COVID19− groups. Signif-
icant gene sets were defined as those with an FDR ≤ 0.1. Visualization and network anal-
yses were performed using the EnrichmentMap application for Cytoscape 3.8.0 (https ://
cytos cape.org/) according to default parameters [18]. To determine the degree of simi-
larity between gene sets (nodes), the combined coefficient using a merged version of the 
Jaccard and overlap similarity coefficients was used to define edges (i.e. connecting lines) 
between the nodes (cut-off 0.375).
Population statistics
Medians (IQRs) and frequency (%) were utilized to describe patient baseline charac-
teristics for continuous and categorical variables, respectively. Continuous variables 
were compared using two-tailed Mann–Whitney U or Kruskal–Wallis tests, as appro-
priate. Categorical variables were compared using Fisher’s exact test. SPSS version 26 
(IBM Corp., Armonk, NY, USA) was used to perform all population statistics and p-val-
ues < 0.05 were considered statistically significant.
Results
We profiled the leukocyte transcriptome of 7 COVID19 + ICU patients (median years 
of age = 60.0, IQR = 56.0, 67.0) and 7 age- and sex-matched COVID19− ICU patients 
(median years of age = 60.0, IQR = 53.0, 63.0; p = 0.520) on day 1 of admission to the 
ICU. Baseline demographic characteristics, comorbidities, laboratory values, and chest 
X-ray findings are reported in Table 1. Compared to the COVID19 + , COVID19− ICU 
patients were more likely to have an increased white blood cell count, specifically neu-
trophils; however, COVID19 + ICU patients were more likely to have bilateral pneumo-
nias. While SARS-CoV-2 was confirmed by PCR in 100% of COVID19 + ICU patients, 
an infectious agent was only identified in 43% of COVID19− ICU patients and was ’sus-
pected’ in the remaining 57%. The mortality rate was 29% for COVID19 + ICU patients.
Principal components analysis revealed clustering of samples based on SARS-CoV-2 
PCR status, suggesting that changes in gene expression in circulating leukocytes 
in COVID19 + patients were unique to SARS-CoV-2, rather than common to sep-
sis or/and ARDS in critically ill COVID19− patients (Fig.  1a). GSA yielded 1,311 dif-
ferentially expressed genes (false discovery rate < 0.055 and a > 1.5-fold increase or 
decrease in expression; Additional file  3: Table  S1), 254 of which were upregulated 
and 1057 of which  were downregulated (Fig.  1b, c) in the circulating immune cells of 
COVID19 + patients.
Functional enrichment analysis performed in Enrichr (https ://maaya nlab.cloud /Enric 
hr/) suggested an overrepresentation of genes that characterize CD14 + monocytes and 
CD33 + myeloid cells (Additional file 4: Table S2) in COVID19 + patients. Further func-
tional analysis using Metascape (Fig. 2) revealed an overall upregulation in IFN mediated 
gene transcription in leukocytes of COVID19 + ICU patients, whereas genes associated 
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with protein translation were all downregulated in the leukocytes of COVID19 + relative 
to COVID19− ICU patients (Fig. 3). These findings were independently confirmed using 
an alternative analysis tool, Reactome (Additional file  5: Figure S3), indicating highly 
reproducible responses.
GSEA was then used to identify differentially expressed gene sets in the entire data 
set. After correcting for multiple comparisons, GSEA revealed that about 68.5% of 
genes were decreased compared to 31.5% that were increased in COVID19+ com-
pared to COVID19− ICU  patients. Furthermore, a total of 7/50 gene sets were 
Table 1 Subject demographics and clinical data
Continuous data are presented as medians (IQRs). MODS Multiple Organ Dysfunction Score, SOFA Sequential Organ Failure 
Assessment Score, COPD Chronic Obstructive Pulmonary Disease, WBC white blood cell
Variable COVID19 + patients COVID19– patients p-value
n 7 7 1.000
Age in years 60.0 (56.0, 67.0) 60.0 (53.0, 63.0) 0.520
Sex 5F:2 M 5F:2 M 1.000
MODS 4.0 (1.0, 7.0) 5.0 (3.0, 7.0) 0.400
SOFA 4.0 (3.0, 9.0) 5.0 (4.0, 11.0) 0.334
Comorbidities, n (%)
 Hypertension 4 (57.1) 6 (85.7) 0.559
 Diabetes 2 (28.6) 3 (42.9) 1.000
 Chronic kidney disease 1 (14.3) 0 (0) 1.000
 Cancer 1 (14.3) 1 (14.3) 1.000
Admission laboratory values
 WBC (× 109/L) 8.2 (3.8, 12.9) 19.3 (13.6, 24.8) 0.018*
 Neutrophils (× 109/L) 7.3 (3.8, 11.1) 13.0 (11.7, 22.2) 0.025*
 Lymphocytes (× 109/L) 0.7 (0.6, 1.0) 1.4 (0.4, 1.7) 0.608
 Platelets (× 109/L) 202 (119, 225) 212 (145, 291) 0.565
 Haemoglobin (g/L) 122 (104, 137) 123 (98, 137) 0.898
 Creatinine (µmol/L) 68 (45, 184) 65 (49, 80) 0.609
 p:F ratio 124 (69, 202) 172 (132, 304) 0.317
Admission chest X-ray findings, n (%)
 Bilateral pneumonia 7 (100) 1 (14.3) 0.005*
 Unilateral pneumonia 0 (0) 4 (57.1) 0.070
 Interstitial infiltrates 0 (0) 1 (14.3) 1.000
 Normal 0 (0) 1 (14.3) 1.000
Sepsis diagnosis
 Suspected 0 (0) 4 (57.1) 0.070
 Confirmed 7 (100) 3 (42.9) 0.070
Interventions during study
 Antibiotics 7 (100) 7 (100) 1.000
 Anti-virals 3 (42.9) 0 (0) 0.192
 Steroids 1 (14.3) 2 (28.6) 1.000
 Vasoactive medications 5 (71.4) 5 (71.4) 1.000
 Renal replacement therapy 1 (14.3) 0 (0) 1.000
 High-flow nasal cannula 3 (42.9) 1 (14.3) 0.559
 Non-invasive mechanical ventilation 4 (57.1) 7 (100) 0.192
 Invasive mechanical ventilation 5 (71.4) 6 (85.7) 1.000
ICU outcome
 Survived 5 (71.4) 7 (100) 0.462
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negatively enriched while 26/50 were positively enriched (FDR < 10%). In addition to 
overrepresentation of genes associated with IFN signalling (Fig.  4), GSEA identified 
enrichment for gene sets involved in TNF and IL6 signalling, complement signalling, 
apoptosis, and coagulation pathways in COVID19 + ICU patients (Fig.  4). In contrast, 
gene transcripts contributing to metabolic pathways involving protein synthesis, oxida-
tive phosphorylation, and DNA repair were consistently and markedly downregulated 
Fig. 2 Metascape functional analysis of transcriptional differences in circulating leukocytes from 
COVID19 + and COVID19− critically ill patients. The list of 1311 differentially expressed genes was submitted 
to Metascape using express analysis of Homo sapiens gene IDs. A subset of enriched terms was selected and 
rendered as a network plot, where terms with a similarity > 0.3 were connected by edges. The network was 
visualized using Metascape. Each node represents an enriched term and coloured first by its cluster ID (a) and 
then by its p-value (b)
Fig. 3 Gene expression and predicted protein–protein interaction networks of transcriptional differences 
in circulating leukocytes from COVID19 + and COVID19− critically ill patients. Differentially expressed genes 
(1311) were submitted to the Reactome Pathway Browser, resulting in the identification of three major 
pathway classifications (shown as heat maps, left to right): a interferon (interferon signalling, interferon alpha/
beta signalling, anti-viral mechanism by IFN-stimulated genes); b cell cycle regulation (cell cycle, mitotic, 
G1/S transition, mitotic G1 phase and G1/S transition, G1/S-specific transcription); and c protein translation/
ribosomes (GTP hydrolysis and joining of the 60S ribosomal subunit, formation of a pool of free 40S subunits, 
formation of the ternary complex, the 43S complex, eukaryotic translation initiation, Cap-dependent 
translation initiation, L13a-mediated translational silencing of ceruloplasmin expression, eukaryotic 
translation elongation, peptide chain elongation, translation initiation complex formation, response of 
EIF2AK4 (GCN2) to amino acid deficiency). The gene lists corresponding to these three pathway classifications 
were submitted to String-db (https ://strin g-db.org/cgi/input .pl) to predict the protein–protein interaction 
networks (shown below each corresponding heat map)
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in COVID19 + ICU patients (Fig. 4). GSEA was also used to identify enrichment of spe-
cific transcription factor (TF) binding sites in the leukocytes of COVID19 + relative to 
COVID19− ICU patients that may shed light on the observed disease-associated modi-
fications of leukocyte transcriptomes. Network analysis confirmed an overrepresen-
tation of genes that shared cis-regulatory sequences for serum response factor (SRF), 
E2F/1, nuclear factor kappa beta (NFκB), and cAMP response element-binding protein 
(CREB) in the COVID19 + data set (Additional file 6: Figure S4).
Enrichment Map and the Autoannotate function in Cytoscape 3.8.0 was used to per-
form network analyses to visualize higher level changes in biological organization. This 
approach identifies tightly connected nodes, or clusters, indicating shared relationships 
between differentially expressed genes (shared gene membership). We used an FDR 
cut-off of ≤ 0.1 and a nominal p-value of ≤ 0.01 to select genes sets for network analy-
sis. Figure 5 highlights the top network clusters and key biological processes that were 
differentially regulated in COVID19 + vs. COVID19− ICU patients. Notable clusters/
processes identified as being either positively or negatively enriched in COVID19 + ICU 
patients by these analyses included platelet activation (20 gene sets), neurotrophin sig-
nalling (29 gene sets), SUMOylation and ubiquitination of proteins (27 gene sets), and 
toll receptor cascades (12 gene sets).
Discussion
In this study, we compared leukocyte transcriptional profiling of COVID19 + to 
COVID19− ICU patients. The study was designed in such a way that control COVID19− 
ICU patients were grossly clinically indistinguishable from the COVID19 + patients. 
Despite similar clinical features, the most striking result was that patients were distin-
guishable based on leukocyte transcriptional profile (e.g. unique molecular features 
Fig. 4 Gene set enrichment analysis of transcriptional differences in circulating leukocytes from 
COVID19 + and COVID19− critically ill patients. a Histogram of Hallmark gene set enrichment analysis. A total 
of 26/50 gene sets were positively enriched in the phenotype COVID positive ( +) and 7/50 gene sets showed 
positive enrichment for the COVID negative (−) phenotype. Differentially regulated gene sets were ranked by 
normalized enrichment score (NES) and plotted against the –log10 of the false discovery rate (FDR q value). 
b Heat maps of the top 12 gene sets in the ranking list in a. Red indicates positive enrichment and blue 
indicates negative enrichment of gene transcripts.
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could be picked up in those that were positive for the SARS-Cov2 virus vs. those that 
were not). One difference that was evident between COVID19 + and COVID19− ICU 
patients was the identification of an infectious agent. However, while no agent was iden-
tified in 57% of the COVID19− ICU patients, the presence of an infectious agent was 
suspected. Moreover, this is not uncommon in sepsis as the literature suggests that in at 
least 30% of sepsis cases, a pathogen cannot be detected [19].
The consistent differences between the transcriptional profiles of COVID19 + patients 
and COVID19− patients with non-COVID lung injury that we observed are similar to 
previous clinical reports indicating that COVID19 + patients do not exhibit “typical” 
symptoms of acute respiratory distress [3], and that COVID19 + patients have a unique 
inflammatory profile [5, 6]. As indicated by both single-gene based and gene set (GSEA) 
approaches, the major disease-specific transcriptional responses of leukocytes in criti-
cally ill COVID19 + ICU patients were: (i) a robust overrepresentation of IFN related 
gene expression; (ii) a marked decrease in the transcriptional level of genes contributing 
to protein synthesis and bioenergy metabolism; and (iii) the dysregulated expression of 
genes associated with coagulation, platelet function, complement activation, and TNF/
IL6 signalling.
Functional enrichment analysis also highlighted a marked shift in cellular population 
within the circulation with a significant enrichment for transcriptional profiles associ-
ated with CD14 + monocytes and CD33 + myeloid cells, underscoring the lymphope-
nia observed in COVID19 + ICU patients. Further, compared to COVID19− patients, 
COVID19 + patients exhibited an overall decrease in the expression of genes associated 
with these cell types, suggesting a potential shift in the innate immune response. Moreo-
ver, these data can be interpreted to indicate a decrease in CD14 + monocyte activation 
Fig. 5 Correlation network generated from transcriptional differences in circulating leukocytes derived 
from COVID19 + and COVID19− critically ill patients. Each node represents a unique gene set and the 
edges represent the coefficient of similarity between gene sets above a defined threshold. Markov Cluster 
Algorithm (MCL) clustering analyses revealed groups of gene transcript nodes, where platelet activation, 
neurotrophin signalling, toll-like receptor signalling cascades, and sumoylation/ubiquitination pathways were 
identified as the top four nodes. Red indicates positive enrichment of gene transcripts and blue indicates 
negative enrichment of gene transcripts.
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and/or a decrease in overall CD14 + monocyte number within COVID19 + ICU patients 
compared to COVID19− ICU patients, who exhibited increased white blood cells.
Disease-specific alterations in IFN signalling have been previously identified in 
patients with COVID19 [20], and our recent publication on a similar patient cohort iden-
tified significantly increased levels of IFNs in the plasma of COVID19 + ICU patients 
compared to both age- and sex-matched COVID19− ICU patients and healthy controls 
[5]. Classical type I (α/β) and type II (γ) IFN signalling through IFN receptors and Janus 
kinase-signal transducer and activator of transcription (JAK-STAT) pathways activate 
IFN-stimulated genes (ISGs), in part through nuclear factor kappa B (NFkB) signalling, 
that mediate a complex web of responses that include, but are not limited to, pathogen 
sensing, sensitization, desensitization and inhibition of viral entry [21–23]. Toll-like 
receptor (TLR)-mediated cascades, independently identified in our network correlation 
analyses, are one of the major pathogen sensing pathways activated by type I IFN signal-
ling. In parallel with the induction of ISG transcription, IFN signalling promotes a global 
shutdown in translation and cellular RNA degradation to induce the death of virus-
infected cells. This correlates with the upregulation of E2F genes that regulate the core 
transcriptional machinery driving cell cycle progression, dictating the timing and fidel-
ity of genome replication and ensuring genetic material is accurately passed on through 
each cell division cycle [23].
While transient activation of IFN signalling pathways often occurs during viral infec-
tions, sustained IFN signalling can paradoxically promote viral persistence and induce 
both immune suppression and chronic inflammation [24]. For example, chronically 
increased IFN levels have been implicated in the inhibition of T cell proliferation and 
chemokine release, and the TRAIL-induced apoptosis of CD4 + T cells during both 
infectious and non-infections pathologies [25, 26]. While TRAIL (TNFSF10) expression 
was not identified as significantly increased in our patient population, there was a trend 
towards enhanced TNFSF10 expression in COVID19 + compared to COVID19- patients 
at day 1 of ICU admission. In addition to TRAIL, sustained type I IFN levels can also 
induce the expression of pro-apoptotic molecules while enhancing the immunosuppres-
sive actions of dendritic cells, monocytes, and macrophages through augmented expres-
sion of cytokines [24]. Thus, sustained IFN signalling can effectively “derail” the normal 
innate immune response and promote viral persistence at both the cellular and tissue 
level.
Potentially relevant to COVID19 + ICU patients, chronically high levels of IFNγ have 
also been detected in, and postulated to be causal of, macrophage activation syndrome 
(MAS). Moreover, dysregulated and persistent macrophage activation has been previ-
ously described in COVID19 + patients [27]. In this scenario, SARS-CoV-2 infection 
would lead to defects in lymphocyte cytolytic activity [28], where natural killer (NK) cells 
and cytolytic CD8 + T cells exhibit reduced capacity to lyse infected and otherwise acti-
vated antigen presenting cells, resulting in prolonged cell–cell interactions with persis-
tent amplification of pro-inflammatory cytokine cascades [29]. The subsequent cytokine 
response induces macrophage activation and haemophagocytic lymphohistiocytosis, 
ultimately contributing to multi-organ dysfunction and death [30]. While this is a com-
pelling working hypothesis, larger scale and more focussed analyses will be required to 
test this possibility.
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Transcriptomic signatures are expected to differ depending on the specific cell popu-
lations being examined, which can account for variation in overall trends that can be 
identified. For example, a recent study by Jeannet and colleagues [31] focused on lym-
phocytes and suggested that these cells are immunosuppressed and exhausted. However, 
as our understanding of the immunopathology of COVID19 evolves, it has been sug-
gested that uncontrolled macrophage and monocyte activation due to a dysfunctional 
interferon response to SARS-CoV-2 infection plays a key role in subsequent inflamma-
tory response and organ injury [32–34]. It is likely that this is the predominant signature 
in our patients. Moreover, our data supports that dysregulation of macrophage/mono-
cyte responses, sustains and enhances activation of interferon response genes in mono-
cytes and macrophages driving immunosuppression and dysfunction in lymphocytes 
[27, 29, 35, 36].
In addition to IFN, our data also identified a significant enrichment in genes associated 
with TNF signalling in COVID19 + compared to COVID19- patients. TNF signalling is a 
critical pathway in the regulation of the pro-inflammatory response following infection, 
where it typically is observed in the very early stages of infection and returns to basal 
levels as the infection progresses [37, 38]. With respect to COVID19, previous work 
by our group in a similar patient population identified a persistent elevation of circu-
lating TNF in COVID19 + patients [5]. Together, these studies suggest that augmented 
TNF signalling may be key in COVID19 and may provide a potential therapeutic target 
through the use of neutralizing antibodies or small molecule inhibitors as has been pre-
viously suggested [5, 39].
One of the key clinical features of COVID19 is upregulation of the pro-thrombotic 
phenotype and microvascular complications, leading to COVID19-associated coagulop-
athy [7]. This is characterized by venous, arterial, and microvascular thrombosis despite 
the use of anti-coagulant therapies [40–46]. Our study provides compelling evidence 
of COVID19-associated changes in coagulation-related gene expression levels that 
may exacerbate thrombosis caused by endothelial cell injury and platelet activation in 
COVID19 + ICU patients [7]. In particular, disease-specific upregulation of SERPINE1 
(encoding plasminogen activator inhibitor-1; PAI-1), VWF (von Willebrand factor), and 
GZMB (Granzyme B) gene expression levels in COVID19 + ICU patients may contribute 
to thrombotic disorders in COVID19 patients [5, 47]. Granzyme B is a serine protease 
that may be involved in thrombus formation through induction of endothelial damage 
and endothelial cell apoptosis [48], which we recently found to be the most discrimina-
tory inflammatory analyte for identifying COVID19 status in ICU patients [5]. Assessed 
in combination, the COVID19-associated changes in the expression of genes involved in 
platelet activation, haemostasis, fibrin clot formation, platelet cytosolic calcium levels, 
and Thromboxane A2 expression, in parallel with transcriptional changes in genes regu-
lating chemokine levels and granulocyte activation, identified in this study may provide 
both a unique transcriptional profile that identifies and reflects the pathophysiological 
mechanism(s) involved, and potential therapeutic targets for the treatment of patients 
with life-threatening COVID19 infections.
We have also identified a decrease in the expression of genes required for heme 
metabolism in the immune cells from COVID19 + ICU patients. These findings may 
be relevant to viral sequestration of iron from haemoglobin. Many viruses require 
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iron for replication, and utilize a variety of mechanisms to decrease cellular iron 
metabolism to increase iron availability. Cell free iron can bind to damage recognition 
receptors, and in addition to driving oxidative stress, cell-free haemoglobin has been 
shown to be injurious in the lungs of patients with ARDS [49].
As shown in Fig. 5, COVID19 + ICU patients also exhibited changes in the expres-
sion of genes regulating the addition of ubiquitin moieties and/or small ubiquitin-like 
moieties (SUMO) to proteins. Viruses rely heavily on the host’s cellular replication 
machinery, including the ability to by-pass and/or exploit cellular ubiquitin and 
SUMOylation conjugating systems, to successfully proliferate and achieve infection. 
Many viruses are able to target essentially every step of ubiquitination and SUMOyla-
tion processes, including the activation of genes that encode ubiquitin ligases or other 
molecules that alter the intracellular pools of free ubiquitin and SUMOs available for 
conjugation to proteins that modulate replication processes [50].
Another intriguing network correlation identified was neurotrophin signalling. 
Neurotrophins are structurally related neuropeptides and include nerve growth factor 
(NGF) and brain-derived neurotrophic factor (BDNF). These peptides play key roles 
in the survival and development of peripheral and central nervous systems. In the 
context of COVID19, neurotrophins are likely to be components of a neuroimmune 
response to infection, as shown previously in the early stages of the H1N1 influenza 
pandemic [51]. Neurotrophins have been previously implicated in the pathogenesis 
of other lung conditions associated with airway inflammation and hyperreactivity, 
such as asthma [52]. Moreover, it is plausible that the dysregulation of neurotrophin-
encoding genes in COVID19 + ICU patients may be linked to neural damage result-
ing from SARS-CoV-2 infection of the brainstem and/or other central nervous system 
(CNS) sites [53].
Collectively, the data from our exploratory study identify a unique leukocyte tran-
scriptional profile in COVID19 + ICU patients vs. COVID19− ICU patients. However, it 
is important to note that, while novel, these findings are derived from a study with some 
design limitations. First, all the data in this study were derived from critically ill patients 
at a single admission time point. As such, we were unable to assess any transcrip-
tional changes associated with ICU admission or track these changes over the course 
of the patients time in the ICU. Second, the study included only 7 COVID19 + and 7 
COVID19− patients. However, even with what could be considered to be a small sam-
ple size, we were still able to identify a unique transcriptional profile associated with 
SARS-CoV-2 infection. Importantly, these studies, which are supported by previous 
findings by our group [5–7], will be hypothesis-generating for future studies of disease 
severity and/or outcome. Third, the COVID19-specific transcriptional profiles reported 
here have not been independently verified. However, our findings were consistent with 
previous studies by ourselves and others comparing COVID19 patients with healthy 
controls, and with the COVID19-induced changes in plasma proteins identified in our 
recently published studies from a similar patient cohort [5–7, 11, 31, 47, 54]. For exam-
ple, increased expression of the GZMB and SDC1 genes, as well as the increased expres-
sion of multiple genes encoding IFN signalling molecules, are supported by findings of 
increased abundance of granzyme B, syndecan-1, and IFNs, respectively, in the plasma 
of COVID19 + vs. COVID19− ICU patients [5–7].
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We also utilized multiple approaches to analyse the transcriptome data, including both 
single-gene as well as gene set enrichment analysis (i.e. GSEA). GSEA applies a thresh-
old-free overrepresentation analysis strategy to evaluate genome wide expression pro-
files and to determine whether a priori defined sets of genes show statistically significant, 
cumulative changes in gene expression that correlate with phenotype (COVID19 + vs. 
COVID19−). While single-gene methods can identify individual gene effects, this 
approach may be undermined by the variance across individuals seen in complex disease 
states. GSEA is complementary to single-gene analysis in providing a framework with 
which to examine changes in higher levels of biological organization, such that altera-
tions in gene expression associated with a disease can manifest at the level of biological 
pathways or co-regulated gene sets, rather than individual genes. Thus, while we did not 
independently assess the changes in expression of individual genes identified in these 
RNAseq analyses, the collective support provided by previous publications in combina-
tion with the use of multiple analysis techniques validates our overall findings.
Conclusion
In summary, we report a unique transcriptome in COVID19 + ICU patients that can be 
distinguished from those of COVID19− patients despite the heterogeneity and timing 
of presentation/admission to the ICU. This unique transcriptome, which can be meas-
ured using common laboratory techniques suggesting it may be amenable to future 
point-of-care tests, is driven by enhanced IFN signalling, dysregulated protein synthesis, 
and increased platelet activation and coagulation. Finally, given the significant impact of 
COVID19 critical illness on society, our novel data may provide guidance in future tar-
geted studies exploring therapeutics in parallel with validation of our findings in larger 
COVID19 + cohorts.
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Additional file 1: Figure S1. Data analysis pipeline in Partek Flow. Unaligned reads (fastq files) were imported and 
their attributes (status, date, and patient) were added manually. Pre-alignment QA/QC provided information on the 
total number of reads, average length, average quality (Q) scores, % N and %GC content. Bowtie2 was used to align 
the reads to a database of rRNA sequences to assess the effectiveness of the ribosomal RNA (rRNA) reduction step 
in the assay. Using default parameters, reads were aligned to the hg19 reference index using STAR 2.7.3a. Transcript 
abundance was quantified from the aligned reads using the Expectation/Maximization algorithm and annotated to 
a transcriptome, in this case RefSeq transcripts 93–2020-02-03. 18,040 genes were identified in the dataset at this 
point. The output was raw gene counts for each gene. The coverage report provided information on the genome 
coverage and number of on-target and off-target reads. Post-alignment QA/QC assembled the results and metrics 
from previous QC reports, as well as providing information regarding the average number of alignments per read 
and the percentage of unique, non-unique and unaligned reads. Filtered features were based on the Q1 feature dis-
tribution, and features with ≤ 18 reads were excluded in a conservative approach to reduce noise. The data were nor-
malized using Trimmed Mean of M values (TMM) and by the addition of 1.0 × 10–4 to avoid zero values. Data dimen-
sionality reduction allowed for visualization in three dimensions and was performed with principal component 
analysis (PCA) using all components and features contributing equally (all the features were standardized to a mean 
of 0 and a standard deviation of 1). Based on the PCA, the batch effect of the date the two runs were performed was 
removed, as well as the interaction of data and status, using Partek’s batch effect remover algorithm (calculating 
the variation attributed to the factor(s) being removed then adjusting the original values to remove the variation). 
Gene-specific analysis (GSA) is a statistical modelling approach used to test for differential expression of genes or 
transcripts. The goal of GSA is to identify a statistical model that is the best for a specific gene transcript, and then 
use the best model to test for it’s differential expression. Genes with a fold change of < −1.5-fold or > 1.5-fold, and 
an FDR step-up p-values of ≤ 0.0545 were filtered for further biological analysis with Partek, as well as with various 
third party tools. Gene set enrichment was used to find gene sets (Gene Ontology terms and KEGG pathways) that 
were overrepresented in the filtered gene list, based on Fisher’s exact test. Hierarchical clustering was performed by 
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clustering samples and features using the average linkage and Euclidean distance. Features were standardized (shift 
mean to 0 and scale standard deviation to 1) to normalize the data and facilitate data display in heat maps.
Additional file 2: Figure S2. Dissimilarity plots of COVID positive and negative samples, before (left) and after (right) 
the batch effect removal tool was used visualize hidden structures in the data—such as the presence of outliers or 
persistent batch effects after correction. Entries with lower dissimilarities (higher similarity) are plotted darker.
Additional file 3: Table S1. Differentially expressed genes (COVID19 + vs. COVID19-)
Additional file 4: Table S2. Top significant cell types from Enrichr (p < 0.05)
Additional file 5: Figure S3. Differentially expressed genes (1,311) were submitted to the Reactome Pathway 
Browser and the top 25 pathways from Reactome (https ://react ome.org/) were identified. The number of genes in 
each pathway is represented by the blue bars, and the FDR p-value for each pathway is represented by the orange 
line.
Additional file 6: Figure S4. Transcription factor analysis data set where nodes represent unique gene sets contain-
ing genes known to share 5′ cis-regulatory sequences for the binding of specific transcription factors. The edges 
represent the coefficient of similarity between the gene sets above a defined threshold (Jaccard and overlap similar-
ity coefficient cut-off 0.375). Groups of nodes were obtained by Markov Cluster Algorithm (MCL) clustering into 
gene modules. The highlighted nodes were associated with a given transcription factor, suggesting a co-regulatory 
network. Red indicates positive transcript enrichment and blue indicates negative transcript enrichment.
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